Virologic Outcomes of Lamivudine/Dolutegravir in Virologically suppressed persons with expected or confirmed resistance to Lamivudine (VOLVER clinical trialGESIDA 11820)
R. De Miguel,M. De Lagarde,J. L. Blanco,A. Pinto-Martinez,R. Montejano,A. Gutierrez Liarte,R. Navarro-Soler,E. Canas-Ruano,A. Inciarte,L. Martin-Carbonero,A. Imaz,C. Hernandez Gutierrez,A. Ocampo,M. Jimenez-Gonzalez,P. Gil,R. Delgado,F. Pulido,J. R. Arribas
